Atropine is a treatment for myopia control, but do combination treatments such as with orthokeratology increase the efficacy? Learn about how well it works, which concentration, for whom it works best, side effects, treatment duration and more.
This meta-analysis of 5 studies of 1, 6 and 12 months duration found that slower axial growth is evident when using orthokeratology in conjunction with atropine as a combined therapy compared to orthokeratology alone. A slowing effect of 0.09mm was seen with the combined approach for up to a 12 month follow-up period. Longer data was not available for the meta-analysis.
Contact lens options are ideal for higher myopes. What about when they have moderate astigmatism as well? This case discusses the evidence base for myopia control options which correct for astigmatism, along with patient-specific considerations and whether a combination treatment with atropine is needed.
In this clinical case, the practitioner is considering whether to start a young patient on a monotherapy or go straight to combination treatment. The discussion includes the recent studies on combination treatment and the best approach for utilizing atropine in view of orthokeratology wear.
Myopia control is vital for children with fast myopia progression. What are the key risk factors for faster myopia progression? What clinical findings indicate a more proactive myopia management strategy may be required? This case describes risk factors and evidence-based treatment options for fast myopia progressors.
Contact lenses offer numerous functional, psychological and myopia controlling benefits for children. What should you do if a parent or patient says no to contact lenses for their child, and you consider it an ideal option? How can you approach communication to convey the safety and benefits?
Should we change myopia control strategy when there is myopia progression? Before making the decision, it’s important to evaluate the evidence base in judging treatment success, and considering the best course of management based on both myopia correction as well as myopia control.
When atropine isn’t working as a monotherapy, is it valuable to combine it with a myopia controlling contact lens? Could switching from atropine to a contact lens be the better option? In this post on the Facebook discussion group, a colleague sought opinions on combining atropine and MiSight contact lenses.
MCS was hesitating fitting OrthoK to a patient who showed inferior corneal steepening. Her main concern was that OrthoK may induce corneal ecstasia/keratoconus in the future and whether there is a link between OrthoK and keratoconus.
Welcome to Part 2 of the ARVO 2019 Research Roundup! For article abstracts and more info, please click on the headings.
